553 related articles for article (PubMed ID: 23698361)
1. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
[TBL] [Abstract][Full Text] [Related]
2. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
3. Structure-based development of PDEδ inhibitors.
Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
[TBL] [Abstract][Full Text] [Related]
4. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
[TBL] [Abstract][Full Text] [Related]
5. Identification of pyrazolopyridazinones as PDEδ inhibitors.
Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
7. Fixing a hole where the Ras gets in.
Iwig JS; Kuriyan J
Cell; 2013 Jun; 153(6):1191-3. PubMed ID: 23746837
[TBL] [Abstract][Full Text] [Related]
8. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
9. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.
Murarka S; Martín-Gago P; Schultz-Fademrecht C; Al Saabi A; Baumann M; Fansa EK; Ismail S; Nussbaumer P; Wittinghofer A; Waldmann H
Chemistry; 2017 May; 23(25):6083-6093. PubMed ID: 27809361
[TBL] [Abstract][Full Text] [Related]
10. Anticancer drugs: A new approach for blocking KRAS.
Tse MT
Nat Rev Drug Discov; 2013 Jul; 12(7):506. PubMed ID: 23787956
[No Abstract] [Full Text] [Related]
11. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex.
Bello M; Correa-Basurto J; Vargas-Mejía MÁ
Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570
[TBL] [Abstract][Full Text] [Related]
14. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.
Chandra A; Grecco HE; Pisupati V; Perera D; Cassidy L; Skoulidis F; Ismail SA; Hedberg C; Hanzal-Bayer M; Venkitaraman AR; Wittinghofer A; Bastiaens PI
Nat Cell Biol; 2011 Dec; 14(2):148-58. PubMed ID: 22179043
[TBL] [Abstract][Full Text] [Related]
15. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908
[TBL] [Abstract][Full Text] [Related]
16. Cancer: Drug for an 'undruggable' protein.
Baker NM; Der CJ
Nature; 2013 May; 497(7451):577-8. PubMed ID: 23698372
[No Abstract] [Full Text] [Related]
17. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
Cheng J; Li Y; Wang X; Dong G; Sheng C
J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling.
Yelland T; Garcia E; Parry C; Kowalczyk D; Wojnowska M; Gohlke A; Zalar M; Cameron K; Goodwin G; Yu Q; Zhu PC; ElMaghloob Y; Pugliese A; Archibald L; Jamieson A; Chen YX; McArthur D; Bower J; Ismail S
J Med Chem; 2022 Feb; 65(3):1898-1914. PubMed ID: 35104933
[TBL] [Abstract][Full Text] [Related]
19. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
[TBL] [Abstract][Full Text] [Related]
20. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
